JP2005513155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005513155A5 JP2005513155A5 JP2003556394A JP2003556394A JP2005513155A5 JP 2005513155 A5 JP2005513155 A5 JP 2005513155A5 JP 2003556394 A JP2003556394 A JP 2003556394A JP 2003556394 A JP2003556394 A JP 2003556394A JP 2005513155 A5 JP2005513155 A5 JP 2005513155A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrimidin
- lower alkyl
- bromo
- yloxy
- ethoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 18
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 102000002045 Endothelin Human genes 0.000 claims 8
- 108050009340 Endothelin Proteins 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 8
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000003282 alkyl amino group Chemical group 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 239000004480 active ingredient Substances 0.000 claims 5
- 125000004414 alkyl thio group Chemical group 0.000 claims 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010012655 Diabetic complications Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010038419 Renal colic Diseases 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000007675 cardiac surgery Methods 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 239000000460 chlorine Chemical group 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 201000005917 gastric ulcer Diseases 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- UOAMFKUSJGXAJT-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UOAMFKUSJGXAJT-UHFFFAOYSA-N 0.000 claims 2
- GKNRICGPGVNSOP-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 GKNRICGPGVNSOP-UHFFFAOYSA-N 0.000 claims 2
- MFFJWNLTOJTLIW-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 MFFJWNLTOJTLIW-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000007232 portal hypertension Diseases 0.000 claims 2
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 238000007631 vascular surgery Methods 0.000 claims 2
- -1 5-bromo-pyrimidin-2-yloxy Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010058872 Fungal sepsis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000005149 cycloalkylsulfinyl group Chemical group 0.000 claims 1
- 125000005366 cycloalkylthio group Chemical group 0.000 claims 1
- 125000005241 heteroarylamino group Chemical group 0.000 claims 1
- 125000005150 heteroarylsulfinyl group Chemical group 0.000 claims 1
- 125000005368 heteroarylthio group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 1
- 125000004468 heterocyclylthio group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- HXWDHNAEVKWPQR-UHFFFAOYSA-N n-[5-(2-chloro-5-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 HXWDHNAEVKWPQR-UHFFFAOYSA-N 0.000 claims 1
- XPDOBCREVDGWNE-UHFFFAOYSA-N n-[5-(2-chloro-5-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 XPDOBCREVDGWNE-UHFFFAOYSA-N 0.000 claims 1
- KUQAVFMCAIVQEC-UHFFFAOYSA-N n-[5-(3-methoxyphenoxy)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]butane-1-sulfonamide Chemical compound C=1C=CC(OC)=CC=1OC=1C(NS(=O)(=O)CCCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 KUQAVFMCAIVQEC-UHFFFAOYSA-N 0.000 claims 1
- YBZPGENLNBOPON-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]methanesulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)C)=NC=NC=1OCCOC1=NC=C(Br)C=N1 YBZPGENLNBOPON-UHFFFAOYSA-N 0.000 claims 1
- RZCPIUOIBGUJAA-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 RZCPIUOIBGUJAA-UHFFFAOYSA-N 0.000 claims 1
- OLLFRCFQYOKNBX-UHFFFAOYSA-N n-[5-(4-bromophenyl)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 OLLFRCFQYOKNBX-UHFFFAOYSA-N 0.000 claims 1
- KHGHGINGZRDHQJ-UHFFFAOYSA-N n-[5-(4-methylphenyl)-6-[2-(5-methylsulfanylpyrimidin-2-yl)oxyethoxy]pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(SC)C=N1 KHGHGINGZRDHQJ-UHFFFAOYSA-N 0.000 claims 1
- DXEAVENYJZCWCC-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-chloro-5-methoxyphenoxy)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 DXEAVENYJZCWCC-UHFFFAOYSA-N 0.000 claims 1
- GQNDHPXIBSVUKS-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-chloro-5-methoxyphenoxy)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C(OC)=CC=C(Cl)C=1OC=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 GQNDHPXIBSVUKS-UHFFFAOYSA-N 0.000 claims 1
- CMPCSJBKUBWQGQ-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CC)=NC(C=2N=CC=CN=2)=NC=1OCCOC1=NC=C(Br)C=N1 CMPCSJBKUBWQGQ-UHFFFAOYSA-N 0.000 claims 1
- MPKQPJVJPRYNED-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(2-methoxyphenoxy)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=CC=C(OC)C=1OC=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 MPKQPJVJPRYNED-UHFFFAOYSA-N 0.000 claims 1
- SRMDKQOXEKHAEJ-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-chlorophenyl)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(Cl)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 SRMDKQOXEKHAEJ-UHFFFAOYSA-N 0.000 claims 1
- UIDBISUHXOJSFR-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-chlorophenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(Cl)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UIDBISUHXOJSFR-UHFFFAOYSA-N 0.000 claims 1
- CSYJJVCQYGWAPM-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]ethanesulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 CSYJJVCQYGWAPM-UHFFFAOYSA-N 0.000 claims 1
- KWYKEXOLXHZRMJ-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]methanesulfonamide Chemical compound C1=CC(C)=CC=C1C1=C(NS(C)(=O)=O)N=CN=C1OCCOC1=NC=C(Br)C=N1 KWYKEXOLXHZRMJ-UHFFFAOYSA-N 0.000 claims 1
- UZJPUBLRNMORBF-UHFFFAOYSA-N n-[6-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-5-(4-methylphenyl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound C=1C=C(C)C=CC=1C=1C(NS(=O)(=O)CCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 UZJPUBLRNMORBF-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
- 208000013223 septicemia Diseases 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0200002 | 2002-01-02 | ||
| EPPCT/EP02/00002 | 2002-01-02 | ||
| PCT/EP2002/013970 WO2003055863A1 (en) | 2002-01-02 | 2002-12-10 | Novel alkansulfonamides as endothelin antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005513155A JP2005513155A (ja) | 2005-05-12 |
| JP2005513155A5 true JP2005513155A5 (enExample) | 2006-01-26 |
| JP4769418B2 JP4769418B2 (ja) | 2011-09-07 |
Family
ID=8164767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003556394A Expired - Fee Related JP4769418B2 (ja) | 2002-01-02 | 2002-12-10 | 新規なアルカンスルホンアミド類 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7323465B2 (enExample) |
| JP (1) | JP4769418B2 (enExample) |
| KR (1) | KR100940432B1 (enExample) |
| CN (1) | CN100537546C (enExample) |
| AR (1) | AR037943A1 (enExample) |
| AT (1) | ATE381545T1 (enExample) |
| AU (1) | AU2002361033B8 (enExample) |
| BR (1) | BR0215424A (enExample) |
| CA (1) | CA2471220C (enExample) |
| DE (1) | DE60224223T2 (enExample) |
| ES (1) | ES2297040T3 (enExample) |
| HU (1) | HUP0500082A2 (enExample) |
| IL (2) | IL162534A0 (enExample) |
| MX (1) | MXPA04006457A (enExample) |
| MY (1) | MY138502A (enExample) |
| NO (1) | NO327220B1 (enExample) |
| NZ (1) | NZ533693A (enExample) |
| TW (1) | TWI248436B (enExample) |
| WO (1) | WO2003055863A1 (enExample) |
| ZA (1) | ZA200404927B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523540A (ja) * | 2007-04-03 | 2010-07-15 | ファイザー・インク | スルホンアミドおよびその医薬組成物 |
| IT1393136B1 (it) * | 2009-03-11 | 2012-04-11 | Sifa Vitor S R L | Procedimento per la preparazione del bosentan |
| US20100256371A1 (en) * | 2009-04-02 | 2010-10-07 | Glenmark | Processes for the preparation of bosentan and its intermediates thereof |
| AR077999A1 (es) * | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
| EP2907811A1 (en) * | 2014-02-14 | 2015-08-19 | Actelion Pharmaceuticals Ltd. | Process for manufacturing pyrimidine sulfamide derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5739333A (en) | 1995-05-16 | 1998-04-14 | Tanabe Seiyaku Co., Ltd. | Sulfonamide derivative and process for preparing the same |
| JP3013752B2 (ja) * | 1995-05-16 | 2000-02-28 | 田辺製薬株式会社 | スルホンアミド誘導体 |
| AU703386B2 (en) * | 1995-12-20 | 1999-03-25 | Astellas Pharma Inc. | Arylethenesulfonamide derivatives and drug composition containing the same |
| WO1998003488A1 (en) * | 1996-07-23 | 1998-01-29 | Shionogi & Co., Ltd. | Novel pyrimidine compounds and drug compositions |
| JP3116347B2 (ja) * | 1996-11-13 | 2000-12-11 | 田辺製薬株式会社 | 医薬組成物 |
| WO1998057938A1 (en) * | 1997-06-19 | 1998-12-23 | Yamanouchi Pharmaceutical Co., Ltd. | Substituted lower alkanesulfonamide derivatives and pharmaceutical composition containing the same |
| AU775194B2 (en) * | 1999-09-03 | 2004-07-22 | Actelion Pharmaceuticals Ltd | Bis-sulfonamides |
| GB0023074D0 (en) * | 2000-09-20 | 2000-11-01 | Pfizer Ltd | Pyridazines |
-
2002
- 2002-12-10 DE DE60224223T patent/DE60224223T2/de not_active Expired - Lifetime
- 2002-12-10 IL IL16253402A patent/IL162534A0/xx unknown
- 2002-12-10 AU AU2002361033A patent/AU2002361033B8/en not_active Ceased
- 2002-12-10 BR BR0215424-2A patent/BR0215424A/pt not_active IP Right Cessation
- 2002-12-10 HU HU0500082A patent/HUP0500082A2/hu unknown
- 2002-12-10 NZ NZ533693A patent/NZ533693A/en not_active IP Right Cessation
- 2002-12-10 MX MXPA04006457A patent/MXPA04006457A/es active IP Right Grant
- 2002-12-10 US US10/500,485 patent/US7323465B2/en not_active Expired - Fee Related
- 2002-12-10 CA CA2471220A patent/CA2471220C/en not_active Expired - Fee Related
- 2002-12-10 CN CNB028266447A patent/CN100537546C/zh not_active Expired - Fee Related
- 2002-12-10 WO PCT/EP2002/013970 patent/WO2003055863A1/en not_active Ceased
- 2002-12-10 ES ES02795133T patent/ES2297040T3/es not_active Expired - Lifetime
- 2002-12-10 JP JP2003556394A patent/JP4769418B2/ja not_active Expired - Fee Related
- 2002-12-10 KR KR1020047010218A patent/KR100940432B1/ko not_active Expired - Fee Related
- 2002-12-10 AT AT02795133T patent/ATE381545T1/de active
- 2002-12-19 AR ARP020105030A patent/AR037943A1/es active IP Right Grant
- 2002-12-26 TW TW091137487A patent/TWI248436B/zh not_active IP Right Cessation
- 2002-12-30 MY MYPI20024923A patent/MY138502A/en unknown
-
2004
- 2004-06-15 IL IL162534A patent/IL162534A/en not_active IP Right Cessation
- 2004-06-22 ZA ZA2004/04927A patent/ZA200404927B/en unknown
- 2004-07-29 NO NO20043215A patent/NO327220B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6513078B2 (ja) | 新規ヒストンデアセチラーゼインヒビター | |
| US7868023B2 (en) | Thiophene sulfoximines, compositions thereof, and methods of treating complement-mediated diseases and conditions | |
| JP2004517855A5 (enExample) | ||
| CO5611172A2 (es) | Stents recubiertos con n-{5-[4-(4-metil-piperazino-metil) -benozilamido]-2-metilfenil}-4-(3-piridil)-2-pirimidin-amina | |
| JP2010526103A5 (enExample) | ||
| RU2005111589A (ru) | Производные 1-пиридин-4-илмочевины | |
| ES2694375T3 (es) | Composiciones para el tratamiento de la hipertensión y/o de la fibrosis | |
| JP2005513155A5 (enExample) | ||
| JP2005502644A5 (enExample) | ||
| CA2440557C (en) | Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof | |
| CN103249400B (zh) | 用于治疗青光眼和高眼压症的腺苷a1激动剂 | |
| RU2005120769A (ru) | Пиримидинсульфамиды и их использование в качестве антагонистов эндотелиальных рецепторов | |
| US20040152753A1 (en) | Methods of use for novel sulfur containing organic nitrate compounds | |
| US20090075949A1 (en) | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | |
| CA2471220A1 (en) | Novel alkansulfonamides as endothelin antagonists | |
| CA2586106C (en) | Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases | |
| JP2008519826A5 (enExample) | ||
| JP4175887B2 (ja) | 新規血管狭窄治療剤または予防剤 | |
| CN102920698A (zh) | 用于与低氧或局部缺血有关的眼科疾病的组合物 | |
| WO2001092234A1 (en) | Pyrazinone thrombin inhibitors | |
| JP4249128B2 (ja) | 全身性炎症反応症候群の治療用医薬組成物 | |
| JP2015526493A (ja) | 冠動脈バイパス移植術を受けることが予定されている患者の非ｓｔ上昇型急性冠症候群の治療において使用するためのオタミキサバン | |
| WO2007066678A1 (ja) | 角結膜障害治療剤 | |
| HK1150775A (en) | Oxazolidinones for the treatment and/or prophylaxis of heart failure | |
| WO2016204239A1 (ja) | ＴＡＦＩａ阻害剤とプラスミノーゲンアクチベータの組み合わせ |